MK-2206 window of opportunity study in breast cancer

Por Akcakanat, Argun, Meric-Bernstam, Funda
Publicado no Ann Transl Med (2018)

Targeting translation initiation in breast cancer

Por Akcakanat, Argun, Hong, David S, Meric-Bernstam, Funda
Publicado no Translation (Austin) (2014)

The rapamycin-regulated gene expression signature determines prognosis for breast cancer

Por Akcakanat, Argun, Zhang, Li, Tsavachidis, Spiridon, Meric-Bernstam, Funda
Publicado em 2009

RAPAMYCIN REGULATES THE PHOSPHORYLATION OF RICTOR

Por Akcakanat, Argun, Singh, Gopal, Hung, Mien-Chie, Meric-Bernstam, Funda
Publicado em 2007

Targeting the PI3-kinase/Akt/mTOR Signaling Pathway

Por Hassan, Burhan, Akcakanat, Argun, Holder, Ashley M., Meric-Bernstam, Funda
Publicado em 2013

Comparison of Akt/mTOR Signaling in Primary Breast Tumors and Matched Distant Metastases

Por Akcakanat, Argun, Sahin, Aysegul, Shaye, Alexandra N., Velasco, Marco A., Meric-Bernstam, Funda
Publicado em 2008

RNA-binding specificity of Y-box protein 1

Por Dong, Jinjiang, Akcakanat, Argun, Stivers, David N., Zhang, Jiexin, Kim, Doyil, Meric-Bernstam, Funda
Publicado no RNA Biol (2009)

Effect of Leucine Restriction on Akt/mTOR Signaling in Breast Cancer Cell Lines In Vitro and In Vivo

Por Singh, Gopal, Akcakanat, Argun, Sharma, Chandeshwar, Luyimbazi, David, Naff, Katherine A., Meric-Bernstam, Funda
Publicado no Nutr Cancer (2011)

eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling

Por Soni, Alpana, Akcakanat, Argun, Singh, Gopal, Luyimbazi, David, Zheng, Yuhuan, Kim, Doyil, Gonzalez-Angulo, Ana, Meric-Bernstam, Funda
Publicado em 2008

Targeting PI3Kβ alone and in combination with chemotherapy or immunotherapy in tumors with PTEN loss

Por Owusu-Brackett, Nicci, Zhao, Ming, Akcakanat, Argun, Evans, Kurt W., Yuca, Erkan, Dumbrava, Ecaterina Ileana, Janku, Filip, Meric-Bernstam, Funda
Publicado no Oncotarget (2020)

TAK228 enhances antitumor activity of eribulin in triple negative breast cancer

Por Owusu-Brackett, Nicci, Evans, Kurt W., Akcakanat, Argun, Yuca, Erkan, Tapia, Coya, Rizvi, Yasmeen Qamar, Dumbrava, Ecaterina Ileana, Janku, Filip, Meric-Bernstam, Funda
Publicado no Oncotarget (2019)

Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer

Por Meric-Bernstam, Funda, Chen, Huiqin, Akcakanat, Argun, Do, Kim-Anh, Lluch, Ana, Hennessy, Bryan T, Hortobagyi, Gabriel N, Mills, Gordon B, Gonzalez-Angulo, Ana Maria
Publicado em 2012

Epithelial to mesenchymal transition is associated with rapamycin resistance

Por Holder, Ashley M., Akcakanat, Argun, Adkins, Farrell, Evans, Kurt, Chen, Huiqin, Wei, Caimiao, Milton, Denai R., Li, Yisheng, Do, Kim-Anh, Janku, Filip, Meric-Bernstam, Funda
Publicado no Oncotarget (2015)

High stearoyl-CoA desaturase 1 expression is associated with shorter survival in breast cancer patients

Por Holder, Ashley M., Gonzalez-Angulo, Ana M., Chen, Huiqin, Akcakanat, Argun, Do, Kim-Anh, Symmans, W. Fraser, Pusztai, Lajos, Hortobagyi, Gabriel N., Mills, Gordon B., Meric-Bernstam, Funda
Publicado em 2012

Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer

Por Sangai, Takafumi, Akcakanat, Argun, Chen, Huiqin, Tarco, Emily, Wu, Yun, Do, Kim-Anh, Miller, Todd W., Arteaga, Carlos L., Mills, Gordon B., Gonzalez-Angulo, Ana Maria, Meric-Bernstam, Funda
Publicado em 2012

Selinexor (KPT-330) demonstrates anti-tumor efficacy in preclinical models of triple-negative breast cancer

Por Arango, Natalia Paez, Yuca, Erkan, Zhao, Ming, Evans, Kurt W., Scott, Stephen, Kim, Charissa, Gonzalez-Angulo, Ana Maria, Janku, Filip, Ueno, Naoto T., Tripathy, Debu, Akcakanat, Argun, Naing, Aung, Meric-Bernstam, Funda
Publicado no Breast Cancer Res (2017)

Rapamycin regulates Stearoyl CoA Desaturase 1 Expression in Breast Cancer

Por Luyimbazi, David, Akcakanat, Argun, McAuliffe, Priscilla F., Zhang, Li, Singh, Gopal, Gonzalez-Angulo, Ana Maria, Chen, Huiqin, Do, Kim-Anh, Zheng, Yuhuan, Hung, Mien-Chie, Mills, Gordon B., Meric-Bernstam, Funda
Publicado em 2010

Weekly nab-Rapamycin in Patients with Advanced Nonhematologic Malignancies: Final Results of a Phase 1 Trial

Por Gonzalez-Angulo, Ana M., Meric-Bernstam, Funda, Chawla, Sant, Falchook, Gerald, Hong, David, Akcakanat, Argun, Chen, Huiqin, Naing, Aung, Fu, Siqing, Wheler, Jennifer, Moulder, Stacy, Helgason, Thorunn, Li, Shaoyi, Elias, Ileana, Desai, Neil, Kurzrock, Razelle
Publicado em 2013

PIK3CA/PTEN Mutations and Akt Activation as Markers of Sensitivity to Allosteric mTOR inhibitors

Por Meric-Bernstam, Funda, Akcakanat, Argun, Chen, Huiqin, Do, Kim-Anh, Sangai, Takafumi, Adkins, Farrell, Gonzalez-Angulo, Ana Maria, Rashid, Asif, Crosby, Katherine, Dong, Mei, Phan, Alexandria T., Wolff, Robert A., Gupta, Sanjay, Mills, Gordon B., Yao, James
Publicado em 2012

Colocalized Delivery of Rapamycin and Paclitaxel to Tumors Enhances Synergistic Targeting of the PI3K/Akt/mTOR Pathway

Por Blanco, Elvin, Sangai, Takafumi, Wu, Suhong, Hsiao, Angela, Ruiz-Esparza, Guillermo U, Gonzalez-Delgado, Carlos A, Cara, Francisca E, Granados-Principal, Sergio, Evans, Kurt W, Akcakanat, Argun, Wang, Ying, Do, Kim-Anh, Meric-Bernstam, Funda, Ferrari, Mauro
Publicado em 2014